InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Wednesday, 04/24/2019 6:00:04 AM

Wednesday, April 24, 2019 6:00:04 AM

Post# of 807
Q1 Kymriah (USD 45 million) strong demand continued and sales increased driven by new treatment sites in the EU, additional progress with reimbursement, coverage for at least one indication in 14 countries, increased manuf capacity and widened commercial spec in the EU.